/
Oncology
Myeloid Leukemia
254
Pipeline Programs↗
449
Active Trials↗
160
Companies Involved↗
Myeloid Leukemia is a highly competitive landscape with 254 programs across 160 companies. The most active players are Jiangsu Hansoh Pharmaceutical Co., Ltd., Kartos Therapeutics, Inc., Enliven Therapeutics. 42 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical49
Phase 186
Phase 277
Phase 342
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
173 of 231 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 231 classified programs, each share of the total. Modality classified for 95% of 254 pipeline programs.
Analysis
Trial Status
1,356
clinical trials
Completed509 · 38%
Recruiting249 · 18%
Terminated203 · 15%
Unknown status122 · 9%
Active, not recruiting115 · 8%
Not yet recruiting79 · 6%
Other79 · 6%
Clinical Trials
Trial Activity
1356 trials
Page 1 of 91
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)